USAMRIID to study antiviral activity of Claromer technology against national priority biodefense threats
Austin, Texas--(Newsfile Corp. - October 25, 2023) - Maxwell Biosciences, a pre-clinical drug platform company focused on developing biomimetic therapeutics that improve upon natural immune system peptides based on its patented Claromer® technology platform, today announced that they have entered into a Cooperative Research and Development Agreement (CRADA) with the United States Army Medical Research Institute of Infectious Diseases (U.S. Army Medical Research Institute of Infectious Diseases (USAMRIID)). Part of the U.S. Army Medical Research and Development Command, USAMRIID is the U.S Army's premier institution and facility for defensive research into countermeasures against biological warfare, located on Fort Detrick, Maryland.
USAMRIID will test antiviral activity of Maxwell's Claromers to determine potential for either use as chemical lead matter or for further development as an antiviral therapeutic agent in USAMRIID's established in vitro and potentially in vivo infection models. Under this CRADA in support of Maxwell's Screening Program, USAMRIID will initially test four different Claromers against six different biodefense pathogens, including Orthopoxviruses, Filoviruses (including Ebola Viral Disease), Arenaviruses, Paramyxoviruses, Bunyaviruses, and Alphaviruses to determine which, if any of the compounds, will progress to animal testing models.
"Biodefense threats such as Ebola and novel zoonotic infectious diseases such as Avian Flu continue to be a major concern to our military and civilian populations," said J.Scotch McClure, CEO of Maxwell Biosciences. "As a military veteran, I'm proud to lead a team that tirelessly seeks to fill critical unmet needs for more effective therapeutics against the worst global pathogens."
"Our Claromer technology has the potential to replace almost all antibiotics, antifungals and antivirals - and it may help with healthy aging as well," continued McClure. "Signing this CRADA with USAMRIID, the world's preeminent biodefense research organization, is another validation of Maxwell's Claromer technology's potential as an important, disruptive platform technology."
About USAMRIID
Since 1969, USAMRIID has provided leading edge medical capabilities to deter and defend against current and emerging biological threat agents. The Institute is the only laboratory in the Department of Defense equipped to safely study highly hazardous viruses requiring maximum containment at Biosafety Level 4. Research conducted at USAMRIID leads to vaccines, drugs, diagnostics, and training programs that protect both Warfighters and civilians. The Institute's unique science and technology base serves not only to address current threats to our Armed Forces but also is an essential element in the medical response to any future biological threats that may confront our nation. For more information, visit: https://usamriid.health.mil/.
About Maxwell Biosciences
Founded in 2016, Maxwell Biosciences is a pre-clinical drug platform company that develops biomimetic therapeutics – synthetic compounds that mimic and improve upon natural immune system peptides. Inspired by nature, these small molecules have been shown to be effective against Ebola, pan-coronavirus, pan-Influenza A (avian, swine, and human) in destroying not just viruses, but also all tested bacteria, fungi and biofilms with a single compound, while safely avoiding healthy cells. This "One Drug for Many Bugs" technology has been shown to be well-tolerated in human tissues in vitro, and in multiple animal studies, are shelf-stable and do not require a cold-chain. The compounds imitate key components of the immune system, humanity's greatest asset in fighting disease. Maxwell's technology is protected by numerous granted and pending patents and is led by a world-class team of scientists, military veterans, and experienced life science executives. To learn more about Maxwell Biosciences, visit MaxwellBiosciences.com, or follow us on X. Contact Info: 1-855-629-2461; [email protected]
The information contained in this press release does not necessarily reflect the position or the policy of the Government and no official endorsement should be inferred.
To view the source version of this press release, please visit https://www.newsfilecorp.com/release/185129